Skip to Content
  • When Small Trials Convince

    This is a good piece by Bruce Booth in Forbes, and it points out something that’s changing in the biopharma landscape. Readers will have noticed over the… Read More
  • Silicon Stays in the Shadows

    I like this review, but I’ve seen it before. Well, not this exact manuscript, but every few years it seems there’s another one with a similar title… Read More
  • Mongersen Fails

    Readers may recall a post here last year about an odd trial of an antisense drug for Crohn’s disease. Celgene had acquired the drug (mongersen, GED-301)… Read More
  • Alnylam Breaks Through

    As a pioneer in RNAi therapeutics, Alnylam has really had some ups and downs over the years (some of them chronicled on this blog). Today would be one of the &# Read More
  • AstraZeneca Gets the Bad News

    After writing about Merck’s successes (so far) in immuno-oncology, it’s time to write about AstraZeneca’s failure. When the rumors started fly… Read More
Page 1 of 4712345...102030...Last »